P A Newcomb1,2, M Ton3,4, R C Malen3, J L Heffner3, J Labadie3, A I Phipps3,4, A N Burnett-Hartman3,5. 1. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA, 98109, USA. newcomb@fredhutch.org. 2. Department of Epidemiology, University of Washington, Seattle, WA, USA. newcomb@fredhutch.org. 3. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA, 98109, USA. 4. Department of Epidemiology, University of Washington, Seattle, WA, USA. 5. Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA.
Abstract
PURPOSE: This study aimed to characterize patient and clinical factors associated with cannabis (marijuana) use among patients diagnosed with colorectal cancer (CRC). METHODS: We identified CRC patients, diagnosed from 2016 to 2018, using the Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER) cancer registry. CRC patients were recruited via mail and telephone, and participants completed a questionnaire eliciting information on medical history, demographics, and lifestyle factors, including cannabis use. Cancer stage was obtained from SEER registry data. RESULTS: Of 1,433 survey respondents, 339 (24%) were current cannabis users. Current cannabis use was associated with younger age at diagnosis, lower BMI, and a higher prevalence of cigarette smoking and alcohol consumption (p-value < 0.05). Cannabis use was also associated with lower quality of life scores (FACT-C) and advanced-stage cancer (p-value < 0.05). CONCLUSION: Cannabis use among CRC patients was common. Patients with more advanced disease were more likely to report cannabis use. Use also varied by some personal factors, consistent with patterns in the general population. Given the high prevalence of cannabis use among CRC patients, research is needed to determine the benefits and harms of cannabis use for symptom management in cancer patients.
PURPOSE: This study aimed to characterize patient and clinical factors associated with cannabis (marijuana) use among patients diagnosed with colorectal cancer (CRC). METHODS: We identified CRC patients, diagnosed from 2016 to 2018, using the Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER) cancer registry. CRC patients were recruited via mail and telephone, and participants completed a questionnaire eliciting information on medical history, demographics, and lifestyle factors, including cannabis use. Cancer stage was obtained from SEER registry data. RESULTS: Of 1,433 survey respondents, 339 (24%) were current cannabis users. Current cannabis use was associated with younger age at diagnosis, lower BMI, and a higher prevalence of cigarette smoking and alcohol consumption (p-value < 0.05). Cannabis use was also associated with lower quality of life scores (FACT-C) and advanced-stage cancer (p-value < 0.05). CONCLUSION: Cannabis use among CRC patients was common. Patients with more advanced disease were more likely to report cannabis use. Use also varied by some personal factors, consistent with patterns in the general population. Given the high prevalence of cannabis use among CRC patients, research is needed to determine the benefits and harms of cannabis use for symptom management in cancer patients.
Authors: Charles S Cleeland; Fengmin Zhao; Victor T Chang; Jeff A Sloan; Ann M O'Mara; Paul B Gilman; Matthias Weiss; Tito R Mendoza; Ju-Whei Lee; Michael J Fisch Journal: Cancer Date: 2013-09-24 Impact factor: 6.860
Authors: Joseph V Pergolizzi; Robert Taylor; Jo Ann LeQuang; Gianpietro Zampogna; Robert B Raffa Journal: Cancer Chemother Pharmacol Date: 2017-02-24 Impact factor: 3.333
Authors: Mark A Ilgen; Kipling Bohnert; Felicia Kleinberg; Mary Jannausch; Amy S B Bohnert; Maureen Walton; Frederic C Blow Journal: Drug Alcohol Depend Date: 2013-05-15 Impact factor: 4.492
Authors: S Aldington; M Harwood; B Cox; M Weatherall; L Beckert; A Hansell; A Pritchard; G Robinson; R Beasley Journal: Eur Respir J Date: 2008-02 Impact factor: 16.671
Authors: Steven A Pergam; Maresa C Woodfield; Christine M Lee; Guang-Shing Cheng; Kelsey K Baker; Sara R Marquis; Jesse R Fann Journal: Cancer Date: 2017-09-25 Impact factor: 6.860